PL326025A1 - Substituted imidazoles - Google Patents

Substituted imidazoles

Info

Publication number
PL326025A1
PL326025A1 PL96326025A PL32602596A PL326025A1 PL 326025 A1 PL326025 A1 PL 326025A1 PL 96326025 A PL96326025 A PL 96326025A PL 32602596 A PL32602596 A PL 32602596A PL 326025 A1 PL326025 A1 PL 326025A1
Authority
PL
Poland
Prior art keywords
atom
atoms
substituted imidazoles
pharmaceutical composition
formula
Prior art date
Application number
PL96326025A
Other versions
PL184819B1 (en
Inventor
Harold G Selnick
David A Claremon
Nigel J Liverton
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602907.9A external-priority patent/GB9602907D0/en
Priority claimed from GBGB9602975.6A external-priority patent/GB9602975D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PL326025A1 publication Critical patent/PL326025A1/en
Publication of PL184819B1 publication Critical patent/PL184819B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds represented by formula (I), are disclosed. <AR> represents an aromatic group containing 6-10 atoms; and (a) represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom. A pharmaceutical composition is also included. Methods of treating cancer and cytokine mediated diseases are also included.
PL96326025A 1995-10-06 1996-10-02 Substituted imidazoles PL184819B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US505995P 1995-10-06 1995-10-06
US506395P 1995-10-06 1995-10-06
GBGB9602907.9A GB9602907D0 (en) 1996-02-13 1996-02-13 Substituted imidazoles having anti-cancer and cytokine inhibitory activity
GBGB9602975.6A GB9602975D0 (en) 1996-02-13 1996-02-13 Acyl heterocylcic substituted imidazoles having anti-cancer and cytokine inhibitory activity
PCT/US1996/015880 WO1997012876A1 (en) 1995-10-06 1996-10-02 Substituted imidazoles having anti-cancer and cytokine inhibitory activity

Publications (2)

Publication Number Publication Date
PL326025A1 true PL326025A1 (en) 1998-08-17
PL184819B1 PL184819B1 (en) 2002-12-31

Family

ID=27451400

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96326025A PL184819B1 (en) 1995-10-06 1996-10-02 Substituted imidazoles

Country Status (17)

Country Link
EP (1) EP0854870B1 (en)
JP (1) JP3382951B2 (en)
KR (1) KR19990064117A (en)
CN (1) CN1117082C (en)
AT (1) ATE433446T1 (en)
AU (1) AU702146B2 (en)
CA (1) CA2234066C (en)
CZ (1) CZ292707B6 (en)
DE (1) DE69637948D1 (en)
EA (1) EA001203B1 (en)
EE (1) EE03681B1 (en)
IL (1) IL123950A (en)
NO (1) NO981528L (en)
NZ (1) NZ321738A (en)
PL (1) PL184819B1 (en)
SK (1) SK282496B6 (en)
WO (1) WO1997012876A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
JP2000504023A (en) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド Cancer treatment methods
HUP0001140A3 (en) * 1996-12-05 2002-05-28 Amgen Inc Thousand Oaks Substituted pyrimidinone and pyridone compounds and methods of use
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
AR038955A1 (en) * 1996-12-05 2005-02-02 Amgen Inc PIRIMIDINONE AND PIRIDONA SUBSTITUTED COMPOUNDS AND METHODS FOR USE
EP1314731A3 (en) * 1996-12-05 2004-01-02 Amgen Inc. Substituted pyrimidine compounds and their use
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP0988301B1 (en) 1997-06-12 2006-08-09 Aventis Pharma Limited Imidazolyl-cyclic acetals
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
WO1998057966A1 (en) 1997-06-19 1998-12-23 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
NZ526958A (en) 1998-05-22 2004-12-24 Smithkline Beecham Corp Novel 2-alkyl substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
PL351148A1 (en) 1999-04-23 2003-03-24 Takeda Chemical Industries Ltd 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001010865A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. p38MAP KINASE INHIBITORS
JP2003528043A (en) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
DE60103136T2 (en) 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazole derivatives as Raf kinase inhibitors
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
JP2004516237A (en) 2000-06-21 2004-06-03 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー Piperidine amides as modulators of chemokine receptor activity
FR2818978B1 (en) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic MODULATORS OF SODIUM CHANNELS DERIVED FROM 2-PIPERIDYLIMIDAZOLES
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
MXPA05009459A (en) 2003-03-03 2006-05-17 Array Biopharma Inc P38 inhibitors and methods of use thereof.
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
AU2007210073B2 (en) 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
BRPI0908906A2 (en) * 2008-03-21 2019-09-24 Novartis Ag heterocyclic compounds and their uses
US12552768B2 (en) 2021-03-04 2026-02-17 Industry-University Cooperation Foundation Pyridinylpyrazole derivative or pharmaceutically acceptable salt thereof and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9300141A (en) * 1992-01-13 1994-07-29 Smithkline Beecham Corp NOVEL IMIDAZOLE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
AU7629594A (en) * 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease

Also Published As

Publication number Publication date
EE03681B1 (en) 2002-04-15
CN1203590A (en) 1998-12-30
EP0854870A1 (en) 1998-07-29
NZ321738A (en) 1999-11-29
NO981528D0 (en) 1998-04-03
IL123950A (en) 2001-04-30
PL184819B1 (en) 2002-12-31
CN1117082C (en) 2003-08-06
JPH11514353A (en) 1999-12-07
JP3382951B2 (en) 2003-03-04
CA2234066C (en) 2005-12-13
EE9800083A (en) 1998-10-15
SK282496B6 (en) 2002-02-05
ATE433446T1 (en) 2009-06-15
NO981528L (en) 1998-06-05
CA2234066A1 (en) 1997-04-10
KR19990064117A (en) 1999-07-26
EA199800268A1 (en) 1998-12-24
EP0854870B1 (en) 2009-06-10
EP0854870A4 (en) 1999-01-07
EA001203B1 (en) 2000-12-25
AU7514396A (en) 1997-04-28
AU702146B2 (en) 1999-02-11
WO1997012876A1 (en) 1997-04-10
SK43598A3 (en) 1998-11-04
DE69637948D1 (en) 2009-07-23
CZ292707B6 (en) 2003-11-12
CZ104398A3 (en) 1998-07-15

Similar Documents

Publication Publication Date Title
AU3380997A (en) Substituted imidazoles having cytokine inhibitory activity
EA199800268A1 (en) SUBSTITUTED IMIDAZOLES THAT HAVE ANTI-CARTOGENOGENIC AND CYTOKINE-INHIBITING ACTIVITY
HUT71344A (en) Pharmaceutical compositions for inhibiting thrombin containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
MY123354A (en) 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
NO985864L (en) New anti-viral compounds
RU94044436A (en) Method of suppression of skin and vagina atrophy
DE69825603D1 (en) 2,3,5-TRISUBSTITUTED PYRIDINE AS INHIBITORS OF CYCLOOXYGENASE-2
DK0564350T3 (en) 3,5-di-tert-butyl-4-hydroxy flavones, process for their preparation and pharmaceutical compositions having antioxidant and anti-vasoconstrictor action
RU94044454A (en) Inhibitor of autoimmune diseases
NZ270167A (en) Use of benzothiophene derivatives in the preparation of medicaments for treating dysfunctional uterine bleeding
HUT71108A (en) Pharmaceutical compositions against angiogenesis and angiogenic diseases containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for producing them
ES2180564T3 (en) 2-PHENYL-3-AZOILBENZOTIOFENOS TO INCREASE THROMBOMODULIN EXPRESSION.
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner&#39;s syndrome inhibition
GR3031662T3 (en) Anti-seborrhoeic formulation.
RU94044357A (en) Use of 2-phenyl-3-aroylbenzothiophenes for inhibiting weight increase, inducing weight decrease or inhibiting appetite
ATE169217T1 (en) USE OF FURANONE DERIVATIVES TO PREVENT OR TREAT AUTOIMMUNE DISEASES
MX9802732A (en) Substituted imidazoles having anti-cancer and cytokine inhibitory activity.
AU558461B2 (en) Carbamyloxybenzhyrol derivatives
RU94044457A (en) Use of benzthiophenes for hirsutism and alopecia inhibition
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity
IL117083A (en) Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical compositions containing these compounds
KR950008514A (en) Treatment or prophylaxis for diseases involving lipid peroxide
KR950005921A (en) Compositions to Promote Wound Treatment
DE69509657D1 (en) USE OF BENZOTHIOPHENES TO MANUFACTURE A MEDICINE TO REDUCE SCARS IN Wounds Healing